Skip to main content
SpringerLink
Log in

Gastric and Duodenal Neuroendocrine Tumours

  • Chapter
  • First Online:
Evidence-Based Endocrine Surgery

  • 592 Accesses

Abstract

Gastric neuroendocrine tumours (GNETs) arise in enterochromaffin cells. They are rare neoplasms and account for 1% of all gastric neoplasms; however, the incidence has been increasing over the last decade. The increase in diagnosis is due to high incidence of chronic atrophic gastritis and intensive screening on endoscopy. Four types of GNETs have been identified: type 1 is well differentiated and is usually benign; type 2 is associated with multiple endocrine neoplasia (MEN1); type 3 is sporadic, well-differentiated neuroendocrine low-grade carcinoma with a high incidence of metastasis; and type 4 is poorly differentiated, high-grade carcinoma with the worst prognosis. The treatment of GNETs is dependent on the size of the lesion and type, with well-defined treatment strategies for types 2, 3 and 4. The treatment of type 1 GNET is controversial. In advanced inoperable disease treatment, choices are based on tumour factors and presence of symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI, et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust. 2010;193(1):46–52.

    PubMed  Google Scholar 

  2. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol. 2004;35(12):1440–51.

    Article  PubMed  Google Scholar 

  3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.

    Article  CAS  PubMed  Google Scholar 

  4. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–6.

    Article  PubMed  Google Scholar 

  5. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  6. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):87–109.

    Article  PubMed  Google Scholar 

  7. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18. vii

    Article  Google Scholar 

  8. Lawrence B, Kidd M, Svejda B, Modlin I. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep. 2011;13(1):101–9.

    Article  PubMed  Google Scholar 

  9. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113(10):2655–64.

    Article  PubMed  Google Scholar 

  10. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563–9.

    Article  Google Scholar 

  11. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer. 2008;123(4):867–73.

    Article  CAS  Google Scholar 

  12. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, et al. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology. 2009;89(2):217–22.

    Article  CAS  Google Scholar 

  13. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.

    Article  Google Scholar 

  14. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98(1):4–19.

    Article  CAS  Google Scholar 

  15. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28(6):615–20.

    Article  CAS  Google Scholar 

  16. Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davi MV, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Investig. 2012;35(9):817–23.

    CAS  Google Scholar 

  17. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–10.

    Article  CAS  Google Scholar 

  18. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–22.

    Article  PubMed  Google Scholar 

  19. Li AF, Hsu CY, Li A, Tai LC, Liang WY, Li WY, et al. A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies. Cancer. 2008;112(2):274–83.

    Article  Google Scholar 

  20. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99(1):23–32.

    Article  Google Scholar 

  21. Sundler F, Ekblad E, Hakanson R. The neuroendocrine system of the gut—an update. Acta Oncol. 1991;30(4):419–27.

    Article  CAS  Google Scholar 

  22. Waldum HL, Kleveland PM, Sandvik AK, Brenna E, Syversen U, Bakke I, et al. The cellular localization of the cholecystokinin 2 (gastrin) receptor in the stomach. Pharmacol Toxicol. 2002;91(6):359–62.

    Article  CAS  Google Scholar 

  23. Bottcher G, Hakanson R, Nilsson G, Seensalu R, Sundler F. Effects of long-term hypergastrinaemia on the ultrastructure of enterochromaffin-like cells in the stomach of the rat, hamster and guinea pig. Cell Tissue Res. 1989;256(2):247–57.

    Article  CAS  Google Scholar 

  24. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, et al. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology. 1986;90(2):391–9.

    Article  CAS  Google Scholar 

  25. Ryberg B, Carlsson E, Hakanson R, Lundell L, Mattsson H, Sundler F. Effects of partial resection of acid-secreting mucosa on plasma gastrin and enterochromaffin-like cells in the rat stomach. Digestion. 1990;45(2):102–8.

    Article  CAS  Google Scholar 

  26. Wallmark B, Skanberg I, Mattsson H, Andersson K, Sundler F, Hakanson R, et al. Effect of 20 weeks’ ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat. Digestion. 1990;45(4):181–8.

    Article  CAS  Google Scholar 

  27. Tielemans Y, Hakanson R, Sundler F, Willems G. Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats. Gastroenterology. 1989;96(3):723–9.

    Article  CAS  Google Scholar 

  28. Alumets J, El Munshid HA, Hakanson R, Liedberg G, Oscarson J, Rehfeld JF, et al. Effect of antrum exclusion on endocrine cells of rat stomach. J Physiol. 1979;286:145–55.

    Article  CAS  PubMed  Google Scholar 

  29. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41(4):185–200.

    Article  CAS  Google Scholar 

  30. Abraham SC, Carney JA, Ooi A, Choti MA, Argani P. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–75.

    Article  PubMed  Google Scholar 

  31. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.

    Article  PubMed  Google Scholar 

  32. Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S94–7.

    PubMed  Google Scholar 

  33. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–72.

    Article  CAS  PubMed  Google Scholar 

  34. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.

    Article  PubMed  Google Scholar 

  35. Lehy T, Roucayrol AM, Mignon M. Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microsc Res Tech. 2000;48(6):327–38.

    Article  CAS  PubMed  Google Scholar 

  36. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243(6):477–88.

    Article  CAS  PubMed  Google Scholar 

  37. Modlin IM, Kidd M, Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg. 2002;168(12):669–83.

    Article  CAS  PubMed  Google Scholar 

  38. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbeck's Arch Surg. 2011;396(3):299–311.

    Article  Google Scholar 

  39. Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998;122(11):1010–7.

    CAS  PubMed  Google Scholar 

  40. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071–84.

    Article  CAS  PubMed  Google Scholar 

  41. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion. 1995;56(6):455–62.

    Article  CAS  PubMed  Google Scholar 

  42. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84(3):158–64.

    Article  CAS  PubMed  Google Scholar 

  43. Yoshikane H, Tsukamoto Y, Niwa Y, Goto H, Hase S, Mizutani K, et al. Carcinoid tumors of the gastrointestinal tract: evaluation with endoscopic ultrasonography. Gastrointest Endosc. 1993;39(3):375–83.

    Article  CAS  PubMed  Google Scholar 

  44. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.

    Article  PubMed  Google Scholar 

  45. Manfe AZ, Norberto L, Marchesini M, Lumachi F. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids. In Vivo. 2011;25(6):1027–9.

    CAS  PubMed  Google Scholar 

  46. Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepato-Gastroenterology. 2005;52(63):731–41.

    PubMed  Google Scholar 

  47. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14(2):473–82.

    Article  CAS  PubMed  Google Scholar 

  48. Bosman FT, International Agency for Research on C, World Health O. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer2010. Report No.: 9789283224327;9283224329; Contract No.: Report.

    Google Scholar 

  49. Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A, Swan MP. En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy. J Gastroenterol Hepatol. 2009;24(9):1516–21.

    Article  PubMed  Google Scholar 

  50. Merola E, Sbrozzi-Vanni A, Panzuto F, D'Ambra G, Di Giulio E, Pilozzi E, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95(3):207–13.

    Article  CAS  PubMed  Google Scholar 

  51. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78–108.

    Article  CAS  Google Scholar 

  52. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74–87.

    Article  CAS  PubMed  Google Scholar 

  53. Sato Y, Takeuchi M, Hashimoto S, Mizuno K, Kobayashi M, Iwafuchi M, Narisawa R, Aoyagi Y. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepato-Gastroenterology. 2013;60:1524–9.

    PubMed  Google Scholar 

  54. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014;2014:253860.

    PubMed Central  PubMed  Google Scholar 

  55. Sato Y, Imamura H, Kaizaki Y, Koizumi W, Ishido K, Kurahara K, Suzuki H, Fujisaki J, Hirakawa K, Hosokawa O, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377–84.

    Article  PubMed  Google Scholar 

  56. Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D, Crosta C. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis. 2007;39:537–43.

    Article  CAS  PubMed  Google Scholar 

  57. Campana D, Ravizza D, Ferolla P, Faggiano A, Grimaldi F, Albertelli M, Berretti D, Castellani D, Cacciari G, Fazio N, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51:131–9.

    Article  CAS  PubMed  Google Scholar 

  58. Sato Y. Clinical features and management of type I gastric carcinoids. Clin J Gastroenterol. 2014;7(5):381–6.

    Article  PubMed  Google Scholar 

  59. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825.

    Article  PubMed  Google Scholar 

  60. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93(5):368–72.

    Article  PubMed  Google Scholar 

  61. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, Klimstra DS, Brennan MF, Tang LH. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154–60.

    Article  PubMed  Google Scholar 

  62. Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg. 2011;35(8):1879–86.

    Article  PubMed  Google Scholar 

  63. Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab. 1996;81(2):677–83.

    CAS  PubMed  Google Scholar 

  64. Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456–63.

    Article  PubMed  Google Scholar 

  65. Fossmark R, Sørdal Ø, Jianu CS, Qvigstad G, Nordrum IS, Boyce M, Waldum HL. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–75.

    Article  CAS  PubMed  Google Scholar 

  66. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8:e76462.

    Article  CAS  PubMed  Google Scholar 

  67. Miljkovic MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci. 2012;57(1):9–18.

    Article  CAS  PubMed  Google Scholar 

  68. Bordi C, Falchetti A, Azzoni C, D'Adda T, Canavese G, Guariglia A, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol. 1997;21(9):1075–82.

    Article  CAS  PubMed  Google Scholar 

  69. Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg. 2002;386(8):558–69.

    Article  Google Scholar 

  70. Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg. 2004;28(7):652–8.

    Article  PubMed  Google Scholar 

  71. Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg. 1994;18(4):473–9. discussion 9-80

    Article  CAS  PubMed  Google Scholar 

  72. Shinohara T, Ohyama S, Nagano H, Amaoka N, Ohta K, Matsubara T, et al. Minute gastric carcinoid tumor with regional lymph node metastasis. Gastric Cancer. 2003;6(4):262–6.

    Article  PubMed  Google Scholar 

  73. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg. 1996;20(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  74. Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42(8):664–71.

    Article  CAS  PubMed  Google Scholar 

  75. Enzler T, Fojo T. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Semin Oncol. 2017;44(2):141–56.

    Article  CAS  PubMed  Google Scholar 

  76. Olsen IH, Langer SW, Jepsen I, Assens M, Federspiel B, Hasselby JP, et al. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol. 2012;51(1):97–100.

    Article  CAS  PubMed  Google Scholar 

  77. Kolby L, Nilsson O, Ahlman H. Gastroduodenal endocrine tumours. Scand J Surg. 2004;93(4):317–23.

    Article  CAS  PubMed  Google Scholar 

  78. Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006;84(3):212–5.

    Article  CAS  PubMed  Google Scholar 

  79. Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol. 2012;819193(10):15.

    Google Scholar 

  80. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.

    Article  CAS  Google Scholar 

  81. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133(4):375–82.

    Article  Google Scholar 

  82. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.

    Article  Google Scholar 

  83. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.

    Article  CAS  PubMed  Google Scholar 

  84. Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery. 2017;162(3):525–36.

    Article  PubMed  Google Scholar 

  85. Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford). 2015;17(1):23–8.

    Article  Google Scholar 

  86. Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, et al. Liver transplantation for metastatic neuroendocrine tumors: outcomes and prognostic variables. J Surg Oncol. 2015;112(2):125–32.

    Article  PubMed  Google Scholar 

  87. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.

    Article  CAS  PubMed  Google Scholar 

  88. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26(8):985–90.

    Article  PubMed  Google Scholar 

  89. Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IH, van Hillegersberg R. Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg. 2006;24(1):3–9.

    Article  PubMed  Google Scholar 

  90. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13(1):136–40.

    Google Scholar 

  91. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer. 2007;96(1):49–55.

    Article  CAS  Google Scholar 

  92. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87(1):8–19.

    Article  CAS  Google Scholar 

  93. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.

    Article  PubMed  Google Scholar 

  94. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–71.

    Article  CAS  Google Scholar 

  95. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689–96.

    Article  CAS  Google Scholar 

  96. Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Curr Oncol Rep. 2017;19(2):9.

    Article  Google Scholar 

  97. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40(2):78–88.

    Article  Google Scholar 

  98. Öberg K, Knigge U, Kwekkeboom D, Perren A. ESMO Guidelines Working Group Neuroendocrine gastro-entero-pancreatic tumors ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii124–30.

    Google Scholar 

  99. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17(3):49–64.

    Article  CAS  PubMed  Google Scholar 

  100. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Upper Gastrointestinal Surgery, National University Hospital Singapore, Singapore, Singapore

    Asim Shabbir, Jimmy So & Hrishikesh Salgaonkar

Authors
  1. Asim Shabbir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jimmy So
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hrishikesh Salgaonkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asim Shabbir .

Editor information

Editors and Affiliations

  1. Division of Endocrine Surgery, National University Hospital, Singapore, Singapore

    Rajeev Parameswaran

  2. Department of Endocrine Surgery, SGPGI Hospital, Lucknow, India

    Amit Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media Singapore

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shabbir, A., So, J., Salgaonkar, H. (2018). Gastric and Duodenal Neuroendocrine Tumours. In: Parameswaran, R., Agarwal, A. (eds) Evidence-Based Endocrine Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-10-1124-5_35

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1124-5_35

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1123-8

  • Online ISBN: 978-981-10-1124-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation